Trial reportJournal of pain research2025
Efficacy and Safety Comparison of Ulinastatin Versus Flurbiprofen Axetil for Preemptive Analgesia in Reducing Opioid Burden After Total Knee Arthroplasty: A Randomized Controlled Trial.
Trial report in Journal of pain research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- 5E management protocol for enhanced recovery after total knee arthroplasty: stratified RCT.Journal of orthopaedic surgery and research · 2026Trial
- Comment on "Efficacy and Safety Comparison of Ulinastatin versus Flurbiprofen Axetil for Preemptive Analgesia in Reducing Opioid Burden After Total Knee Arthroplasty: A Randomized Controlled Trial" [Letter].Journal of pain research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Total knee arthroplasty (TKA) poses a significant challenge for acute pain. Opioid-based analgesia carries substantial risks, whereas non-steroidal anti-inflammatory drugs (NSAIDs) have adverse effects and ceiling effects. Ulinastatin may be a novel treatment option with improved efficacy and safety. Purpose: To compare the efficacy and safety of single preoperative administration of ulinastatin (UTI), flurbiprofen axetil (FA), and control (saline) in reducing opioid consumption and adverse events in TKA. Patients and Methods: In this prospective, double-blind, placebo-controlled trial, 150 TKA patients were randomized to receive intravenous UTI (30 IU), FA (100 mg), or saline 15 minutes before skin incision. Standardized postoperative analgesia utilizes patient-controlled intravenous analgesia (PCIA) to maintain visual analog scale (VAS) scores ≤30 mm. The primary outcome was cumulative morphine consumption within 72 h postoperatively, while the secondary outcomes included adverse reactions and inflammatory factor levels (IL-6 and IL-10). Results: The final analysis included 149 patients. Median 72-hour morphine consumption was significantly lower with UTI (29.00 [22.50-33.50] mg) than with FA (40.00 [27.50-60.50] mg) and the control (54.40 [46.40-82.80] mg, Conclusion: Single preoperative UTI significantly reduced postoperative morphine consumption (~48%) and adverse reaction risks compared with FA and control by modulating the balance of proinflammatory and anti-inflammatory factors (IL-6 and IL-10). UTI provides an efficient and safe alternative, supporting its inclusion in enhanced recovery after surgery (ERAS) analgesia strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.